Samsara BioCapital’s aTyr Pharma ATYR Stock Holding History

Samsara BioCapital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,750,000	Closed	-$3.67M	–	54
2023 Q1	$3.67M	Buy	+1,750,000	New	+$3.83M	0.76%	24

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Samsara BioCapital's ATYR Position: Q2 2023 in Review

Samsara BioCapital sold out of aTyr Pharma (ATYR) in Q2 2023, closing a stake of 1,750,000 shares — an estimated $3.67M sold.

Samsara BioCapital first reported a position in ATYR in Q1 2023 and held it in 1 quarter. The position peaked at $3.67M in Q1 2023. 41 funds tracked by Wall St. Rank hold ATYR as of Q2 2023.

Samsara BioCapital reported no remaining aTyr Pharma position as of Q2 2023 after selling out during the quarter.
Samsara BioCapital sold 1,750,000 aTyr Pharma shares in Q2 2023, an estimated $3.67M.
Samsara BioCapital first reported a position in aTyr Pharma in Q1 2023 and held it in 1 quarter.
Samsara BioCapital's aTyr Pharma position peaked at $3.67M in Q1 2023.
41 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2023.

Based on Samsara BioCapital's 13F filing for Q2 2023, filed 14 Aug 2023.